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The HER receptors are of therapeutic and prognostic significance in breast cancer, and their function is modulated by cytoplasmic
tyrosine kinases like PTK6 (brk). We performed a retrospective study on archival breast cancer samples from patients with long
follow-up and compared the protein expression between individual HERs and between HERs and the PTK6. Univariate and
multivariate analyses were used to study the prognostic value of parameters. Metastases-free survival of patients for longer than 240
months was inversely associated (Pp0.05) with nodal status, tumour size, and oestrogen receptor status, but was also directly
associated with high protein expression levels of HER4 and PTK6 in Kaplan–Meier analysis. In multivariate analysis for metastases-free
survival of 4240 months, the stepwise selected parameters were tumour size (relative risk 3.1), PTK6 expression (0.4), and number
of positive lymph nodes (1.2). Furthermore, we demonstrated a timedependence of the prognostic value attributed to the
parameters. The HER receptors (HER2,4), but not PTK6, were independent prognostic markers for metastases-free survival at 60
months, whereas at 240 months PTK6 is the strongest prognostic marker. We demonstrate that PTK6 is a prognostic marker of
metastases-free survival in breast cancer, and is independent of the classical morphological and molecular markers of lymph node
involvement, tumour size, and HER2 status.
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The cytoplasmic non-receptor tyrosine kinase (BRK, PTK6),
originally cloned from a human metastatic breast tumour (Mitchell
et al, 1994), shows elevated expression in breast carcinoma cell
lines and in approximately two-thirds of primary breast tumours
(Mitchell et al, 1994; Barker et al, 1997; Llor et al, 1999; Born et al,
2005). Overexpression of PTK6-mRNA positively correlates with
hormone receptor status (Zhao et al, 2003) and HER2/NEU
expression (Born et al, 2005) in breast cancer specimens. Several in
vitro studies of PTK6 point to a possible role in modulating signal
transduction of receptor tyrosine kinases (RTKs): PTK6 expression
increases HER3 phosphorylation and Akt activation (Kamalati
et al, 2000; Zhang et al, 2005), sensitises cells to epidermal growth
factor (EGF) (Kamalati et al, 1996), which activates PTK6
(Kamalati et al, 2000; Chen et al, 2004), and influences the
apoptotic pathway (Haegebarth et al, 2005). There are, however,
several unanswered questions with regard to the structure, activity,
and regulation of PTK6. It was shown by Haegebarth et al (2005)
that PTK6 negatively regulates the activity of RNA-binding
proteins, which may have an impact on the post-transcriptional
regulation of gene expression (Haegebarth et al, 2005). Further-
more, PTK6 possesses sequences that predicted to form Src
homology (SH3 and SH2) domains (Kamalati et al, 1996; Zhang
et al, 2005), suggesting interactions with other proteins. Because of
the known involvement of Src in epithelial tumour development
and structural similarities with Src, it is thought that PTK6 may
play a role in epithelial tumorigenesis (Petro et al, 2004; Zhang
et al, 2005).
The EGF receptor family is composed of four members: EGFR/
HER1/erbB1, HER2/NEU/erbB2, HER3/erbB3, and HER4/erbB4
(Mendelsohn et al, 2000; Hudelist et al, 2003; Lodge et al, 2003;
Abd El-Rehim et al, 2004; Hynes et al, 2005). There is a growing
body of evidence that members of the HER family are involved in
breast cancer development and progression, but the protein
expression pattern of all four HER receptors remains poorly
understood (Bieche et al, 2003; Witton et al, 2003; Abd El-Rehim
et al, 2004; Tovey et al, 2005; Bianchi et al, 2006). HER1 and HER2
have been consistently associated with a poor prognosis (Witton
et al, 2003; Abd El-Rehim et al, 2004; Wiseman et al, 2005),
whereas conflicting evidence is available on the prognostic
significance of HER3 (Kew et al, 2000; Bieche et al, 2003; Tovey
et al, 2004), and HER4 has been more consistently linked to good
prognostic factors (PFs) (Witton et al, 2003; Abd El-Rehim et al,
2004; Tovey et al, 2004).
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sThe EGFR-family molecules are outstanding candidate targets
for tumour therapy. In breast carcinomas it has been shown that
HER2/NEU amplification/overexpression has therapeutic and
prognostic implications (Slamon 1990; Meric et al, 2002; Hudelist
et al, 2003; Witton et al, 2003; Abd El-Rehim et al, 2004; Bianchi
et al, 2006), and that the monoclonal antibody trastuzumab
directed against HER2/NEU is therapeutically active in HER2-
positive breast carcinomas (Meric et al, 2002; Menard et al, 2003).
However, a number of HER2/NEU-positive tumours are not
responsive to HER2/NEU-directed therapy (Menard et al, 2003;
Hynes et al, 2005), indicating that other HER receptors as well as
additional signalling molecules may influence the biological
response to trastuzumab.
Ligand binding by HER/erbB receptors induces the formation of
receptor homo- or heterodimers and activation of the intrinsic
receptor kinase domain, resulting in phosphorylation on specific
tyrosine residues (Olayioye et al, 2000; Hynes et al, 2005) and the
creation of binding sites for proteins containing Src homology
(SH2-/SH3-) domains (Hudelist et al, 2003). The composition of
these receptor dimers is thought to influence both quality and
quantity of downstream signalling pathways and to determine the
cellular response (Olayioye et al, 2000; Hudelist et al, 2003; Hynes
et al, 2005). Further, cytoplasmic protein tyrosine kinases
containing SH2 or SH3 domains may also modify the RTK
signalling (Petro et al, 2004; Zhang et al, 2005). One such non-
receptor protein tyrosine kinase, PTK6 (BRK), is similar to the Src
family kinase and includes structural motifs comprising SH2 and
SH3 domains.
No study has so far tested the hypothesis that PTK6 may have an
impact upon breast cancer prognosis or tested its association with
the HER family of RTKs in breast carcinoma tissue. Because of the
correlation between PTK6 and HER expression, it is possible that
these proteins are together of diagnostic/prognostic relevance. We
investigated the protein expression of the HER1–HER4 receptors
and of the PTK6 in invasive breast carcinomas with long-term
follow-up, and found a previously undescribed time-dependent
prognostic relevance of PTK6 using multivariate analysis.
MATERIALS AND METHODS
Patients and tumour samples
All studies were performed using formalin-fixed, paraffin-
embedded, archival material from invasive breast carcinomas
obtained from 193 patients. The patients age ranged from 27 to 84
years (median 66 years), 52 patients were premenopausal, 141 were
postmenopausal. The hormone receptor status was evaluated
immunohistochemically, revealing that 92 of the tumours were
hormone receptor positive. Histological classification (WHO,
2003) defined 168 tumours as being invasive ductal, not otherwise
specified. The remaining 25 cases were classified as tubular (7),
lobular (9), papillary (3), and medullary (6). A total of 126 cases
were classified as grade 2, 48 cases as grade 3, and 19 cases as grade
1, according to Elston and Ellis (1991). Ninety-nine of the tumours
were lymph-node-negative, 94 were node-positive, and the
majority of the tumours in this study were less than 2cm in size
(n¼135).
Detailed long-term clinical follow-up was available for 105
patients. These patients do not significantly differ from the full
cohort of 193 patients in their clinicohistological parameters.
These patients were all surgically treated, and no patient received
preoperative treatment. Fifty-four patients did not receive post-
operative treatment, whereas adjuvant radio- or chemotherapy was
administered to 47 of the patients, and 14 patients received
antihormonal treatment. The median clinical follow-up of patients
was 144 months (mean 140, range 5–264 months) with 37 patients
relapsing with distant metastases and 15 with local recurrence.
Ethical approval for the study was obtained from the Ethics
Committee of the medical faculty of the Technical University of
Munich.
Tissue microarrays
Tissue Microarray (TMA) construction was performed as de-
scribed (Richter et al, 2000). A haematoxylin- and eosin-stained
section from each paraffin block was used to define representative
tumour regions. Tissue cylinders of 0.6mm
2 in diameter were
punched from each paraffin block and transferred to the recipient
paraffin block using a tissue-arraying instrument (Beecher
Instruments Inc., Silver Spring, MD, USA). From the resulting
TMA blocks, 5-mm sections were cut and transferred to adhesive
slides using the ‘paraffin-tape-transfer-system’ (Instrumedics,
Hackensack, NJ, USA). Both the TMA and punched block were
re-examined to validate representative sampling.
Immunohistochemistry
For immunohistochemistry (IHC), which was performed on all 193
tumours, the following antibodies were used on the TMA sections:
HER1 (erbB1/EGFR; 31G7, Invitrogen, Heidelberg, Germany,
dilution 1:50); HER2 (erbB2; Hercept kit, K5204, DAKO GmbH,
Hamburg, Germany); HER3 (erbB3; H3.105. 5, Stratech, Suffolk,
England, 1:20); HER4 (erbB4; H4.77.16, Stratech, 1:20); PTK6
(BRK, C-17, Santa Cruz Biotechnology, Heidelberg, Germany,
1:100).
Deparaffinisation of the TMA sections, antigen retrieval, and
incubation of the primary antibody was performed in general as
described (Quintanilla-Martinez et al, 2003). For PTK6 IHC, the
deparaffinised slides were microwave-cooked in 0.01 M citrate
buffer (pH 6.0) containing 0.1% Tween 20 at maximum power
(800W) for 8min. Thereafter, sections were washed in Tris-
buffered saline (pH 7.6) containing 5% fetal calf serum (Life
Technologies, Grand Island, NY, USA) for 30min, and the PTK6
antibody was incubated overnight at room temperature. Staining
and counterstaining were by an automated immunostainer
(Ventana Medical System, Tucson, AZ, USA) (Quintanilla-Martinez
et al, 2003).
Tissue staining intensities were scored blind for PTK6, HER3
and HER4 expression by two independent observers using a 4-
point scale, where 0¼no staining, 1¼light staining, 2¼moderate
staining, and 3¼strong staining as published previously (Witton
et al, 2003). HER1 and HER2 expression were scored using widely
accepted criteria that assess the intensity and completeness of
membrane staining (Jacobs et al, 1999; Ellis et al, 2001).
Representative examples of the PTK6 expression classification as
well as expression in normal ducts are given in Figure 1.
Statistics
Correlations among the markers, and between markers and clinical
parameters, were examined by Spearman’s rank correlation test.
Survival analysis (for statistical details, see Allison, 1995) was
performed using distant recurrence-free survival for follow-up
periods of 60, 120, and 240 months, and for disease-free interval of
240 months. The distant recurrence-free survival represents the
interval from surgery to the presentation of distant metastases. The
disease-free interval was defined as the interval from the date of
surgery to the first locoregional recurrence and/or distant
metastases.
For univariate survival analysis Kaplan–Meier curves were
calculated and differences between strata were tested with the
log-rank w
2 value. Multivariate analysis was performed using Cox
proportional hazards regression, using a combined stepwise
selection algorithm (SAS Institute, Cary, NC, USA). All parameters
reaching a significance level of Pp0.2 in Kaplan–Meier analysis
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significance was considered at the Pp0.05 level.
For illustration of the multivariate result the parameters,
weighted by their coefficients, were used to calculate a new
prognostic variable PF (Aubele et al, 1995), and patients were
grouped according to their PF for Kaplan–Meier analysis.
RESULTS
Associations between PTK6 and the HER receptors
Using IHC, strong positivity (2þ,3þ) for the HER1 receptor was
found in only 5% of the tumours, for HER2 in 26%, for HER3 in
74%, for HER4 in 51%, and for PTK6 in 59% (Table 1). As shown
in Table 2, significant correlations were identified among the HER
receptors, and between individual HER receptors and PTK6. The
strongest correlations (Pp0.0001) were found between HER1 and
HER3, between HER2 and PTK6, and between HER4 and PTK6.
The histological grade of tumours was significantly associated with
HER1, HER4, and with PTK6, and an inverse correlation was
identified between the oestrogen receptor (ER) and HER 1
(p0.04). No significant association was present between the nodal
A
D C
B
Figure 1 Representative examples of PTK6 IHC (objective magnification  40) in normal breast epithelium (A), and in breast carcinomas classified as
1þ (B), 2þ (C), and 3þ (D).
Table 1 Frequencies of cases (number/percent of cases) scored as 0/1+/2+/3+ according to their expression of HER receptors and PTK6 in primary
breast carcinomas
HER1/EGFR HER2/neu HER3 HER4 PTK6
0 146/81.1 55/31.6 1/0.6 11/6.4 7/3.8
1+ 25/13.9 74/42.5 43/25.1 72/42.1 67/37.0
2+ 4/2.2 16/9.2 99/57.9 77/45.0 75/41.9
3+ 5/2.8 29/16.7 28/16.4 11/6.4 32/17.7
The highest frequency for each marker is printed bold.
Table 2 Protein expression of HER receptors and PTK6 in invasive
breast carcinomas
HER1 HER2 HER3 HER4 PTK6
HER1 n.s. 0.30 n.s. n.s.
o0.0001
HER2 n.s. 0.16 0.31
0.044 o0.0001
HER3 0.22 0.16
0.004 0.047
HER4 0.35
o0.0001
Grade 0.22 n.s. n.s. 0.21 0.18
0.004 0.005 0.019
Nodal status n.s. n.s. n.s. n.s. n.s.
Tumour size n.s. n.s. n.s. n.s. n.s.
ER  0.18 n.s. n.s. n.s. n.s.
0.023
PrR n.s. n.s. n.s. n.s. n.s.
Correlations among and between HER receptors and PTK6 are given, as well as
relation of markers to clinicopathological parameters (Spearman correlation
coefficients, P-values, n.s.¼not significant, ER¼oestrogen and PrR¼progesteron
receptor status).
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parameters.
To estimate the frequency of HER receptor dimer formation, we
calculated the occurrence of combined overexpression of the
markers, considering those showing immunohistochemical posi-
tivity above the median level as highly overexpressed, whereas a
level below the median was considered as low expression (Table 3).
High-level co-overexpression of the HER family members and the
PTK6 occurred most frequently between HER3 and HER4 (37% of
the cases), between HER3 and PTK6 (40% of cases), and between
HER4 and PTK6 (34% of the cases), whereas all other combina-
tions were below 18% (Table 3).
Prognostic relevance of PTK6 and the HER family
members
Univariate analysis In univariate analyses lymph node status
(P¼0.001), tumour size (P¼0.002), and ER status were all
inversely correlated with an event-free (distant recurrence)
survival of patients longer than 240 months, whereas histological
grade and type and the progesterone receptor status were not
significant (Table 4).
A significant positive correlation with the event-free (distant
recurrence) survival of patients was identified for HER4
(P¼0.015) and for PTK6 (P¼0.001). Figure 2 shows Kaplan–
Meier curves demonstrating distant recurrence-free survival of
patients with high (2þ/3þ) vs low (0/1þ) levels of PTK6 and
HER4 expression, respectively.
Multivariate prognostic analysis Multivariate analysis was used
to assess the influence of markers on the distant recurrence-free
survival of patients, together with that of the clinicopathological
parameters. The stepwise selected parameters for a distant
recurrence-free survival of patients were tumour size (relative risk
3.1), number of positive lymph nodes (1.2), and PTK6 expression
(0.4). The P-values, coefficients, relative risk as well as the 95%
confidence intervals are summarised in Table 5A.
To study the time dependence of the prognostic value of
parameters, we performed multivariate analyses also for 60 months
and for 120 months event-free (distant recurrence) survival. The
results, which are summarised in Table 5B and C, show a strong
time dependence of the prognostic meaning of single parameters.
For an interval of 60 months tumour size (relative risk 4.2),
HER2 expression (1.7), and the HER4 expression (0.4) were each
independently prognostic. At a follow-up of 120 months, the
protein expression of HER4 was no longer significant, instead
PTK6 expression becomes meaningful. Here, the stepwise selected
parameters were tumour size (relative risk 3.4), HER2 (1.5), and
PTK6 (0.4). Summarizing these results, the protein expression of
HER receptors (HER2, HER4) are of strong prognostic value in
short-term survival analysis (60 and 120 months), whereas for a
long interval of 240 months the prognostic value of the PTK6 is the
strongest parameter in addition to tumour size and lymph node
status.
Selecting patients’ disease-free survival as the end point of the
analysis resulted in similar selected parameters with the same
Table 3 High-level co-overexpression of HER receptors and PTK6
(number/percent of cases)
HER2X2 HER3X2 HER4X2 PTK6X2
HER140 9/4.7 29/15.0 20/10.4 22/11.4
HER2X2 33/17.1 27/14.0 34/17.6
HER3X2 71/36.8 77/39.9
HER4X2 66/34.2
Low or high expression was defined being below or above the median level of the
single parameters. The highest frequencies of marker combinations are printed bold.
Table 4 Results of Kaplan–Meier analysis of the single parameters for an
event-free (distant recurrence) survival of patients of 4240 months (P-
values are given)
Parameter P-value
HER1 0.66
HER2 0.14
HER3 0.19
HER4 0.015
a
PTK6 0.001
a
PrR 0.72
ER 0.007
Lymph node status +/  0.001
Tumour size (o20/4¼20mm) 0.002
Histological grade 0.26
Histological type 0.10
Abbreviations: ER¼oestrogen and PrR¼progesteron receptor status.
aHigh
expression corresponds to better prognosis.
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Figure 2 Kaplan–Meier curves for an event-free (distant recurrence)
survival of patients of 4240 months, with low (0/1þ) vs high (2þ/3þ)
protein expression of HER4 (A) and PTK6 (B). The individual groups are:
HER4: low¼42 patients, 55% remain event-free; high¼52 patients, 75%
event-free. PTK6: low¼33 patients, 48% event-free; high¼56 patients,
80% event-free.
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significant prognostic value within the first years, and PTK6 has
weak prognostic meaning for this interval, the HER receptors are
less important and the PTK6 is of high independent prognostic
value for longer intervals (120 and 240 months). The stepwise
selected parameters for a disease-free survival of patients of 4240
months are summarised in Table 5D.
To illustrate one result of the multivariate analysis, a multi-
variate PF was calculated for each individual patient by the
following linear combination of the variables, weighted by their
coefficients (event-free survival 240 months) (Aubele et al, 1995):
PF ¼1:13 tumoursize þ 0:17 no:positivelymphnodes
  0:92 PTK6:
This calculation lead to a continuous variable in a range of  1.63
to 3.24. For Kaplan–Meier analysis, the patients were grouped
according to their PF. The resulting curves (Figure 3) demonstrate
that 91% of patients with low PF ( 1.63 to 0.4) stayed free of
distant metastases, whereas from patients with the highest PF
(1.5–3.24) only 43% remain metastases-free.
DISCUSSION
In this study, we investigated the protein expression of the HER
receptor family (HER1-HER4) and the cytoplasmic tyrosine kinase
PTK6 in archival tissue from 193 breast carcinomas, and tested the
association between markers and patient prognosis.
Studies on HER receptors in breast carcinoma so far focused
mainly on HER1 and HER2, only some groups have evaluated the
expression of the entire HER family (Bieche et al, 2003; Hudelist
et al, 2003; Lodge et al, 2003; Witton et al, 2003; Abd El-Rehim et al,
2004; Wiseman et al, 2005; Bianchi et al, 2006). Those studies have
demonstrated the importance of investigating these related proteins
in the context of their ability to cooperatively modify intracellular
signalling pathways (Bieche et al, 2003; Hudelist et al, 2003; Lodge
et al, 2003; Witton et al, 2003; Abd El-Rehim et al, 2004; Tovey et al,
2005; Wiseman et al, 2005, Bianchi et al,2 0 0 6 ) .W eo b s e r v e di no u r
study strong overexpression 2þ/3þ (2þ/3þ) of the HER
receptors rarely for HER1 (5% of tumours), most frequently for
HER2 (26%), HER3 (74%), and for HER4 (51% of the tumours), in
general in agreement with other studies (Bieche et al, 2003; Witton
et al, 2003; Abd El-Rehim et al, 2004). The frequency of combined
high overexpression 2þ/3þ (2þ/3þ) of individual HER
receptors, which may point to the predominant HER heterodimer-
ization partners in tumours, generally corresponds with other
studies (Alimandi et al, 1995; Holbro, 2003; Hudelist et al, 2003;
Witton et al, 2003; Abd El-Rehim et al, 2004; DiGiovanna et al,
2005; Wiseman et al, 2005). However, a high co-overexpression of
HER3–HER4 in our study was most frequent (37% of tumours)
among the HER receptors. We also could not confirm a relation-
ship between HER1–3 and the ER, as was shown by Witton et al
(2003). Those contrary results may be explained by the different
patient cohorts investigated and the low number of ER-positive
cases in our cohort.
Overexpression of the HER1 and/or HER2 receptors by breast
tumours generally predicts poor patient prognosis (Slamon 1990;
Witton et al, 2003; Abd El-Rehim et al, 2004; Wiseman et al, 2005),
corresponding to our findings. The prognostic significance of
Table 5 Results of the Cox multivariate regression analysis
Parameter v
2 P-value Coefficients Relative risk 95% confidence interval
(A) Total interval (4240 months)
tumour size ( 10, 10–20, 420mm) 8.70 0.003 1.13 3.11 1.46-6.61
PTK6 expression 9.56 0.002  0.92 0.40 0.22–0.71
No. of positive lymph nodes 6.67 0.01 0.17 1.18 1.04–1.35
(B) Interval 120 months
Tumour size ( 10, 10–20, 420mm) 9.40 0.002 1.22 3.39 1.55 7.38
PTK6 expression 10.09 0.002  0.98 0.38 0.21 0.69
HER2 expression 4.71 0.03 0.42 1.52 1.04 2.21
(C) Interval 60 months
Tumour size (10, 10–20, 420mm) 9.20 0.002 1.44 4.22 1.66–10.68
HER4 expression 5.86 0.02  1.04 0.35 0.15–0.82
HER2 expression 4.86 0.03 0.50 1.65 1.06–2.58
(D) Total interval: (4240 months)
Tumour size ( 10, 10–20, 420mm) 4.08 0.04 0.68 1.97 1.02–3.80
PTK6 expression 8.99 0.003  0.79 0.45 0.27–0.76
No. of positive lymph nodes 7.27 0.007 0.17 1.19 1.05–1.34
The summary of stepwise selected parameters is given for an event-free (distant recurrence) survival of 4240 months (A), 120 months (B), and 60 months (C), and for a
disease-free survival of 4240 months (D) (positive coefficients increase, and negative coefficients reduce the risk of an event).
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0 50 100 150 200 250
P
r
o
b
a
b
i
l
i
t
y
0.2
0.4
0.6
0.8
1.0
Overall
Multivariate prognostic factor (PF)
Low
High
Medium
P<0.0001 
Figure 3 Kaplan–Meier curves for the event-free (distant recurrence)
survival of patients of 4240 months. Grouping of patients according to
their multivariate PF resulted in three different risk groups: low PF ( 1.63
to p0.4): 21 patients, 91% remain event-free; medium (0.4 to p1.5): 31
patients, 71% event-free; high PF (1.5–3.24): 28 patients, only 43% event-
free. In addition, the overall event-free survival of all patients is plotted in
grey.
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reports (Kew et al, 2000; Suo et al, 2002; Bieche et al, 2003; Witton
et al, 2003; Abd El-Rehim et al, 2004; Tovey et al, 2004). As, for
example, mRNA overexpression of HER3 and HER4 corresponded
to a worse prognosis (Bieche et al, 2003), whereas combined
HER3–HER4 expression showed association with better outcome
in another study (Abd El-Rehim et al, 2004). Although Wiseman
et al (2005) did not find a relationship between HER4 expression
and patient outcome, in most other studies patients with HER4
overexpression were shown to have increased survival (Suo et al,
2002; Witton et al, 2003; Abd El-Rehim et al, 2004; Tovey et al,
2004). The latter is also in good agreement with our findings here,
where high HER4 expression shows a direct correlation with the
event-free (distant recurrence) survival of patients. Our multi-
variate results further show independent prognostic values for
HER2 and HER4 expression 60 (60 months), and HER2 expression
120 (120 months); however, these results are dependent on the
time interval investigated. A similar time dependence in a
prognostic marker has been reported by Tovey et al (2005).
Investigating ER-positive tamoxifen-treated patients, the authors
demonstrated a time-dependent predictive value of PR and
HER1-3 expression and identified patients at high risk of
tamoxifen resistance only in the first 3 years of treatment. This
time dependency of the prognostic importance of parameters as
well as investigation of different tumour cohorts may explain at
least some of the contradictary results in the literature about
prognostic value of the HER receptors.
Expression of PTK6 in conjunction with that of the HER
receptors has not previously been analysed in breast cancer tissue.
We identified a high co-overexpression of PTK6 less frequently
with HER1 or HER2 (less than 18%), and more frequent with HER4
(34%) and with HER3 (40% of the tumours). We further found a
significant correlation between PTK6 and HER2 at the protein
level, confirming our results in a recent mRNA study (Born et al,
2005). In the study presented here, strong correlations were also
identified between PTK6 and HER3, and HER4, which delivers
further support to the theory that PTK6 plays a functional role in
the HER signalling network.
PTK6 expression and its cellular consequences in tissues appear
paradoxical. In normal breast epithelium, PTK6 is low or
undetectable, but the protein is overexpressed in many breast
carcinomas (Petro et al, 2004; Zhang et al, 2005), suggesting, PTK6
expression is related to carcinogenesis. In contrast, high levels of
PTK6 are expressed in some differentiating epithelial tissues such
as normal gastrointestinal tract, skin (Llor et al, 1999; Haegebarth
et al, 2004), and prostate (Derry et al, 2003), and PTK6 expression
was associated with the degree of differentiation of breast tissue as
indicated by ER expression (Zhao et al, 2003). The correlation of
PTK6 protein expression with the histological tumour grade
observed in our study may also support an association between
PTK6 and cell differentiation.
The most striking result in our study is the previously
undescribed prognostic relevance of the PTK6 protein expression
established using multivariate survival analysis. The time depen-
dence of HER2/HER4/PTK6 expression, relative to survival
analysis, may be an important observation. We hypothesise that
PTK6 could be a cytoplasmic target influencing the biological
response of HER receptor signalling, particularly in the context of
HER4 expression. It is well accepted that different HER receptors
transduce signals through associations with a variety of cytoplasmic
target proteins containing SH2 and/or SH3 domains (Zhang et al,
2005). PTK6 possesses both SH2 and SH3 domains (Kamalati et al,
1996; Zhang et al, 2005), which might enable it to participate in
signalling processes. On the basis of our results here, there appears
to be an interplay between PTK6 as an indicator and the HER
receptors as prognostic markers, in particular HER4. The long-
term prognostic value of PTK6, namely that it is the strongest
prognostic marker at 240 months but not at 60 months may further
support a role for PTK6 in promoting differentiation of tumour
cells. Although HER4 expression (low/high) shows prognostic
power over the first 5 years of follow-up (Figure 2), survival curves
relative to PTK6 expression do not separate during the first 50
months. Longer follow-up, however, suggests a greater prognostic
significance for PTK6 expression than HER4. It should be noted
that, both markers are strongly correlated and both are directly
correlated with favourable clinical outcome, suggesting that they
represent competing drivers in multivariate analysis.
To our knowledge, this is the first study describing an
independent prognostic value for PTK6 in breast carcinomas,
and the association between expression of PTK6 and the HER
receptors. These data suggest that PTK6 may have an important
role in the signal transduction of HER expressing tumour cells
as signalling modifier. Further, our results emphasise not only the
need of investigating all four HERs, but also relevant intracellular
signalling markers, such as CTK’s, which may markedly modify
the biological response to extracellular ligands. Kinomic profiling
of signalling pathways may provide additional insights to the
clinical relevance of key ‘nodes’ in these pathways. The relevance
of the time dependence of the markers employed suggests these
markers select different subgroups of patients with different
prognosis. The combinations of proteomic markers identified here
require further investigation in the context of specific treatment
regimens in a predictive study large enough to probe their
relevance in the context of breast cancer therapy.
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